HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
nebacumab
a human monoclonal IgM antibody that binds specifically to the lipid A domain of endotoxin
Also Known As:
Centoxin; HA-1A monoclonal antibody; septomonab
Networked:
13
relevant articles (
0
outcomes,
2
trials/studies)
Bio-Agent Context: Research Results
Amino Acids, Peptides, and Proteins: 1
Proteins: 484843
Blood Proteins: 12459
Serum Globulins: 553
Immunoglobulins: 30480
Antibodies: 133716
Monoclonal Antibodies: 56412
Humanized Monoclonal Antibodies: 217
nebacumab: 13
Immunoproteins: 43
Immunoglobulins: 30480
Antibodies: 133716
Monoclonal Antibodies: 56412
Humanized Monoclonal Antibodies: 217
nebacumab: 13
Globulins: 3062
Serum Globulins: 553
Immunoglobulins: 30480
Antibodies: 133716
Monoclonal Antibodies: 56412
Humanized Monoclonal Antibodies: 217
nebacumab: 13
Related Diseases
1.
Systemic Inflammatory Response Syndrome (Sepsis Syndrome)
06/13/1994 - "
The goals of this study were to evaluate the criteria for administration of HA-1A monoclonal antibody therapy from the HA-1A trial in patients with suspected gram-negative bacteremia and to evaluate the accuracy with which Bone's criteria for sepsis syndrome identify patients with gram-negative bacteremia.
"
02/13/1993 - "
[Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
"
06/01/1993 - "
The pharmacokinetics and safety of HA-1A (Nebacumab), a human IgM monoclonal antibody with specificity for the lipid A region of endotoxin, were evaluated in a multicenter trial of pediatric patients with sepsis syndrome or septic shock.
"
2.
Bacteremia
12/25/1991 - "
To assess the cost-effectiveness of the HA-1A monoclonal antibody for the treatment of gram-negative bacteremia.
"
06/13/1994 - "
The goals of this study were to evaluate the criteria for administration of HA-1A monoclonal antibody therapy from the HA-1A trial in patients with suspected gram-negative bacteremia and to evaluate the accuracy with which Bone's criteria for sepsis syndrome identify patients with gram-negative bacteremia.
"
07/01/1994 - "
The in vivo neutralizing activities of an anti-lipopolysaccharide (LPS) antibody HA-1A (Centoxin [Centocor, Malvern, PA]), a human immunoglobulin M monoclonal antibody, and of bactericidal/permeability-increasing protein (BPI), an endogenously produced human LPS-neutralizing protein, were studied in a primate model of lethal Escherichia coli bacteremia.
"
3.
Hepatitis
02/01/1994 - "
Two studies implemented hepatitis vaccination programmes, one set up a telephone follow-up of antituberculosis chemoprophylaxis, one developed the official procedures for using epoetin (recombinant human erythropoietin), one initiated clinical discussion meetings about the cost effectiveness of cholesterol-lowering therapy, and one strengthened the decision to register nebacumab (HA-1A, Centoxin), the monoclonal antibody against endotoxin.
"
4.
Sepsis (Septicemia)
12/25/1991 - "
Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis.
"
07/25/1991 - "
The HA-1A monoclonal antibody for gram-negative sepsis.
"
06/01/1994 - "
Sepsis management and antiendotoxin therapy after nebacumab.
"
12/01/1994 - "
The anti-endotoxin antibody, HA-1A (Centoxin), introduced as a treatment for sepsis, was withdrawn because of possible toxicity in some patients.
"
04/05/1993 - "
[Septomonab (Centoxin) in the treatment of gram-negative septicemia].
"
5.
Septic Shock (Toxic Shock Syndrome)
11/14/1994 - "
The French National Registry of HA-1A (Centoxin) in septic shock.
"
06/01/1993 - "
The pharmacokinetics and safety of HA-1A (Nebacumab), a human IgM monoclonal antibody with specificity for the lipid A region of endotoxin, were evaluated in a multicenter trial of pediatric patients with sepsis syndrome or septic shock.
"
Related Drugs and Biologics
1.
Endotoxins
2.
Monoclonal Antibodies
3.
Erythropoietin
4.
Cholesterol
5.
nebacumab
6.
Immunoglobulin M (IgM)
7.
Proteins (Proteins, Gene)
8.
Lipopolysaccharides
9.
Lipid A
10.
bactericidal permeability increasing protein
Related Therapies and Procedures
1.
Therapeutics
2.
Chemoprevention
3.
Immunotherapy